The Japanese government is actively working to restore drug discovery capabilities, aiming to create a revitalized ecosystem that can contribute to domestic and global drug development.
However, these efforts continue to be undermined by remaining constraints on Japan’s rewards for innovation in its drug pricing system – even for novel drugs in key areas like rare diseases and pediatrics, where Japan clearly wants more research and development and faster deployment of innovative remedies.
The Asia Group (TAG) assesses that strict cost disclosure requirements, especially the “zero co-factor” rule under the cost-based price calculation method, directly undermine the government’s goal of bringing innovative new pharmaceutical products to the Japanese market, including the targets laid out in the Japanese government’s five-year plan for the development and approval of pediatric and rare disease drugs.
The Japanese government should consider either adjustments to these rules or introducing an entirely new way of pricing and rewarding innovative medicines to adequately reflect these products’ value at launch. Such changes will facilitate innovative medicines’ faster entry into Japan, ultimately benefiting patients and contributing to the revitalization of Japan’s drug innovation ecosystem.
At their trilateral summit at Camp David on August 18, U.S. President Joe Biden, South...
Shailender Arya in The Hindu Business Line: ‘The conclusion of security and defence partnership between India and EU provides strategic intent and intimate policy guidance for closer defence industrial cooperation between the Indian and European defence industries’
Submit the details below, and our HR team member will get in touch with you shortly.
The Asia Group is an equal opportunity employer where an applicant’s qualifications are considered without regard to race, color, religion, sex, national origin, age, disability, veteran status, genetic information, sexual orientation, gender identity or expression, or any other basis prohibited by law. The Asia Group continually seeks to diversify its staff, particularly to broaden opportunities for individuals from demographic groups that are historically underrepresented in the strategic advisory profession.
Media
Commentary
Japan’s Drug Innovation Incentive Policies: Policy Challenges Undermine Desired Goals (ENG)
Key Takeaways
Listen on:
Related Posts
Shailender Arya in The Hindu Business Line: ‘The conclusion of security and defence partnership between India and EU provides strategic intent and intimate policy guidance for closer defence industrial cooperation between the Indian and European defence industries’
Front Row with George Chen: Davos Declared the Death of “Old World,” But Here is a Glimpse of the “New World”
Rintaro Nishimura quoted in The Straits Times on Japan’s centrist party
Kurt Tong interviewed by CNBC’s Emily Tan on Trump’s Canada tariff threat ahead of USMCA renegotiation